glp 1 agonist review GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read glp-1_analogs [TUSOM | Pharmwiki]

Liraglutide changes postprandial responses of gut hormones involved in the regulation of gallbladder motility

semaglutide improved kidney outcomes in people with type 2 diabetes and chronic kidney disease in FLOW. Joints and musculoskeletal tissue: Mechanical overload from excess weight can cause local pain and inflammatory signaling (often improving with weight reduction)

RELATED: How do I use the SingleCare app

Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea which could increase your risk of low blood sugar

Impact of intentional weight loss in cardiometabolic disease: what we know about timing of benefits on differing outcomes